Approximately 40% of women interviewed in the National Health Interview Survey used complementary and alternative therapies of some kind in the 12 months before taking the survey.
Approximately 40% of women interviewed in the National Health Interview Survey used complementary and alternative therapies of some kind in the 12 months before taking the survey.1 Of women in the midlife Study of Women Across the Nation (SWAN), this figure was nearly 50% at baseline and increased to 80% during the 6-year study.2
In a population-based survey, more than 35% of midlife women had used herbal, homeopathic, or naturopathic medicines, and approximately 12% used them to manage menopausal symptoms.3
Since the main findings for the Women's Health Initiative (WHI) were published in 2002 and in 2004,4,5 more women are choosing not to use hormone therapies (HT) for menopausal symptoms-the use of estrogen and progestin therapies (EPT) decreased by 46% and the use of estrogen therapy (ET) decreased by 28% in US women when comparing use in late 2002 with what had been used before.6
Nonhormonal HT for menopause that may not completely alleviate symptoms are commonly used; women who are perimenopausal and postmenopausal are among the highest users of herbal products. Among the top 10-selling herbal products in the United States in 2004, at least 4 of the 10 products have been used for menopausal symptoms: soy supplements, black cohosh, St John's wort, and ginseng.8
In spite of prevalent use of these products, approximately 70% of women using them do not inform their healthcare providers that they are using them.9
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More